A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Part of paid clinical trials in Sheffield, Alabama.

Sponsor
AstraZeneca
Study ID
NCT07753993
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elecoglipron — DRUG
    Elicoglipron tablet
  • Placebo — DRUG
    Placebo tablet

Study Details

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.

Key Dates

First listed
Aug 10, 2026
Start date
Aug 28, 2026
Status verified
Aug 2026
Primary completion
Oct 4, 2030
Completion
Oct 4, 2030

Study Design

Enrollment
7,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Elecoglipron
    Elecoglipron tablet once daily
  • Active Comparator: Placebo
    Placebo matching Elecoglipron tablet once daily

Primary Outcome Measure

To evaluate the effect of elecoglipron compared with placebo in reducing the risk of the composite of ≥ 50% sustained decline in eGFR, ESKD, or all-cause mortality [ Time Frame: Event-driven, trial is estimated to be up to 4.5 years ]

Central Contacts

Locations (33)

FacilityCityStateZIPSite coordinators
Research SiteSheffieldAlabama35660-
Research SiteSurpriseArizona85374-
Research SiteChula VistaCalifornia91910-
Research SiteWaterburyConnecticut06708-
Research SiteChicagoIllinois60611-
Research SiteTopekaKansas66606-
Research SiteBeltsvilleMaryland20705-
Research SiteBostonMassachusetts02115-
Research SiteTroyMichigan48098-
Research SiteEdinaMinnesota55435-
Research SiteSaint PaulMinnesota55117-
Research SiteEatontownNew Jersey07724-
Research SiteAlbanyNew York12205-
Research SiteBuffaloNew York14215-
Research SiteMineolaNew York11501-
Research SiteMorehead CityNorth Carolina28557-
Research SiteShelbyNorth Carolina28150-
Research SiteStatesvilleNorth Carolina28625-
Research SiteWilmingtonNorth Carolina28401-
Research SiteWilmingtonNorth Carolina28403-
Research SiteMaumeeOhio43537-
Research SiteRapid CitySouth Dakota57701-
Research SiteKnoxvilleTennessee37912-
Research SiteMorristownTennessee37813-
Research SiteArlingtonTexas76015-
Research SiteDallasTexas75246-
Research SiteHoustonTexas77054-
Research SiteLubbockTexas79430-
Research SiteMesquiteTexas75149-
Research SiteSan AntonioTexas78230-
Research SiteShenandoahTexas77384-
Research SiteSouth Salt LakeUtah84115-
Research SiteNorfolkVirginia23502-

Find similar trials in Sheffield, AL

Nationwide
Chronic kidney disease trialsNephrology trialsKidney disease trials
By condition
Chronic kidney disease
By specialty
NephrologyKidney disease

Related Studies